| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Desmethyl Levofloxacin targets bacterial DNA gyrase, an essential enzyme for DNA replication. By inhibiting the supercoiling activity of DNA gyrase, it prevents DNA replication and transcription, leading to bacterial cell death. Its mechanism is identical to that of Levofloxacin.
|
|---|---|
| ln Vitro |
In vitro, Desmethyl Levofloxacin inhibits bacterial DNA gyrase, preventing DNA replication. As a fluoroquinolone metabolite, it retains antibacterial activity. Its activity makes it a valuable tool for studying bacterial DNA replication and developing new antibacterial agents.
|
| ln Vivo |
In vivo, Desmethyl Levofloxacin is a metabolite formed following Levofloxacin administration. Levofloxacin is a broad-spectrum antibiotic used to treat a variety of bacterial infections. The metabolite contributes to the overall antibacterial activity of the parent drug. Its role in vivo is primarily understood through pharmacokinetic studies.
|
| Enzyme Assay |
In vitro enzyme assays for Desmethyl Levofloxacin involve measuring its inhibition of bacterial DNA gyrase activity. The enzyme is incubated with increasing concentrations of the compound, ATP, and a DNA substrate. The supercoiling activity is measured by agarose gel electrophoresis or by using a fluorescent DNA intercalator. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, bacterial cultures are treated with Desmethyl Levofloxacin at various concentrations. Bacterial growth is monitored by measuring optical density at 600 nm. The compound's effects on bacterial DNA replication are assessed by measuring DNA synthesis using radiolabeled thymidine incorporation. Cytotoxicity in mammalian cells is assessed using MTT assays.
|
| Animal Protocol |
In vivo animal studies with Desmethyl Levofloxacin are primarily pharmacokinetic. The compound is administered to rodents, and blood samples are collected at predetermined time points. Plasma concentrations are analyzed by LC-MS/MS. Pharmacodynamic effects can be evaluated in models of bacterial infection.
|
| ADME/Pharmacokinetics |
Desmethyl Levofloxacin (CAS: 117707-40-1) has a molecular weight of 347.34 g/mol and a molecular formula of C17H18FN3O4. Appearance: solid. Purity: ≥95%. Synonyms: Levofloxacin Related Compound A (USP). Storage: -20°C. The compound is a metabolite of Levofloxacin.
|
| Toxicity/Toxicokinetics |
Desmethyl Levofloxacin is a research compound and is not approved for human therapeutic use as a standalone drug. As a metabolite of an approved antibiotic, it shares the toxicity profile of Levofloxacin, which is generally well-tolerated. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Ofloxacin impurity e belongs to the quinoline class of compounds.
Desmethyl Levofloxacin is a metabolite of Levofloxacin, a synthetic fluoroquinolone antibiotic. It inhibits bacterial DNA gyrase, preventing DNA replication. It is not FDA-approved as a standalone drug and is intended for research and analytical use only. |
| Molecular Formula |
C17H18N3O4F
|
|---|---|
| Molecular Weight |
347.34092
|
| Exact Mass |
347.128
|
| CAS # |
117707-40-1
|
| Related CAS # |
Desmethyl Levofloxacin-d8;1217976-18-5
|
| PubChem CID |
10958963
|
| Appearance |
White to off-white solid powder
|
| Density |
1.517g/cm3
|
| Boiling Point |
600.714ºC at 760 mmHg
|
| Flash Point |
317.101ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.677
|
| LogP |
1.595
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
607
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
FC1C=C2C(C(C(=O)O)=CN3C2=C(C=1N1CCN([H])CC1)OC[C@@H]3C)=O
|
| InChi Key |
WKRSSAPQZDHYRV-VIFPVBQESA-N
|
| InChi Code |
InChI=1S/C17H18FN3O4/c1-9-8-25-16-13-10(15(22)11(17(23)24)7-21(9)13)6-12(18)14(16)20-4-2-19-3-5-20/h6-7,9,19H,2-5,8H2,1H3,(H,23,24)/t9-/m0/s1
|
| Chemical Name |
(2S)-7-fluoro-2-methyl-10-oxo-6-piperazin-1-yl-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~8.33 mg/mL (~23.98 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8790 mL | 14.3951 mL | 28.7902 mL | |
| 5 mM | 0.5758 mL | 2.8790 mL | 5.7580 mL | |
| 10 mM | 0.2879 mL | 1.4395 mL | 2.8790 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
